193 related articles for article (PubMed ID: 37248957)
1. An inflammation-associated ferroptosis signature optimizes the diagnosis, prognosis evaluation and immunotherapy options in hepatocellular carcinoma.
Ruan WY; Zhang L; Lei S; Zeng ZR; Yang YS; Cao WP; Hao QY; Lu M; Tian XB; Peng PL
J Cell Mol Med; 2023 Jul; 27(13):1820-1835. PubMed ID: 37248957
[TBL] [Abstract][Full Text] [Related]
2. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
3. The ferroptosis and iron-metabolism signature robustly predicts clinical diagnosis, prognosis and immune microenvironment for hepatocellular carcinoma.
Tang B; Zhu J; Li J; Fan K; Gao Y; Cheng S; Kong C; Zheng L; Wu F; Weng Q; Lu C; Ji J
Cell Commun Signal; 2020 Oct; 18(1):174. PubMed ID: 33115468
[TBL] [Abstract][Full Text] [Related]
4. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy.
Long S; Chen Y; Wang Y; Yao Y; Xiao S; Fu K
Cancer Med; 2023 Jan; 12(2):2134-2147. PubMed ID: 35841206
[TBL] [Abstract][Full Text] [Related]
5. Combination of ferroptosis and pyroptosis to construct a prognostic classifier and predict immune landscape, chemotherapeutic efficacy and immunosuppressive molecules in hepatocellular carcinoma.
Xu L; Zheng Q; Liu W
BMC Cancer; 2022 Mar; 22(1):229. PubMed ID: 35236323
[TBL] [Abstract][Full Text] [Related]
6. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
7. A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma.
Gao L; Xue J; Liu X; Cao L; Wang R; Lei L
Aging (Albany NY); 2021 Nov; 13(22):24866-24881. PubMed ID: 34839280
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.
Hao X; Zheng Z; Liu H; Zhang Y; Kang J; Kong X; Rong D; Sun G; Sun G; Liu L; Yu H; Tang W; Wang X
Redox Biol; 2022 Oct; 56():102463. PubMed ID: 36108528
[TBL] [Abstract][Full Text] [Related]
9. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J; Wang J; Chen X; Zhang L; Peng M
PeerJ; 2024; 12():e16819. PubMed ID: 38317842
[TBL] [Abstract][Full Text] [Related]
10. A novel ferroptosis phenotype-related clinical-molecular prognostic signature for hepatocellular carcinoma.
Deng T; Hu B; Jin C; Tong Y; Zhao J; Shi Z; Zhang T; Deng L; Sun Z; Chen G; Wang Y
J Cell Mol Med; 2021 Jul; 25(14):6618-6633. PubMed ID: 34085405
[TBL] [Abstract][Full Text] [Related]
11. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
12. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
Front Immunol; 2021; 12():719175. PubMed ID: 34603293
[TBL] [Abstract][Full Text] [Related]
13. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.
Li G; Liu Y; Zhang Y; Xu Y; Zhang J; Wei X; Zhang Z; Zhang C; Feng J; Li Q; Wang G
Front Immunol; 2022; 13():929089. PubMed ID: 35874689
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
He Q; Yang J; Jin Y
Front Immunol; 2022; 13():869993. PubMed ID: 35493518
[TBL] [Abstract][Full Text] [Related]
15. A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.
Zhao C; Zhang Z; Tao J
Curr Oncol; 2022 Sep; 29(10):6992-7011. PubMed ID: 36290827
[TBL] [Abstract][Full Text] [Related]
16. A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma.
Xiao J; Liu T; Liu Z; Xiao C; Du J; Zuo S; Li H; Gu H
Cells; 2022 Jul; 11(15):. PubMed ID: 35892599
[TBL] [Abstract][Full Text] [Related]
17. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
18. Prognostic prediction and immune infiltration analysis based on ferroptosis and EMT state in hepatocellular carcinoma.
Liu Z; Wang J; Li S; Li L; Li L; Li D; Guo H; Gao D; Liu S; Ruan C; Dang X
Front Immunol; 2022; 13():1076045. PubMed ID: 36591279
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of an immune-related prognosis signature associated with hypoxia and ferroptosis in hepatocellular carcinoma.
Yang CB; Feng HX; Dai CL
Cancer Med; 2022 Jun; 11(11):2329-2341. PubMed ID: 35092175
[TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of ferroptosis-related gene signature for overall survival prediction in Asian patients with hepatocellular carcinoma.
Wang Z; Zhang L; Xu J; Song W
Clin Transl Oncol; 2023 Mar; 25(3):721-730. PubMed ID: 36319928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
